Balaji Prasad
Stock Analyst at Barclays
(3.09)
# 2,296
Out of 4,853 analysts
147
Total ratings
43.55%
Success rate
0.15%
Average return
Main Sectors:
Stocks Rated by Balaji Prasad
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EOLS Evolus | Maintains: Overweight | $22 → $25 | $9.74 | +156.67% | 8 | Mar 5, 2025 | |
| AMRX Amneal Pharmaceuticals | Maintains: Overweight | $10 → $11 | $7.17 | +53.42% | 5 | Mar 3, 2025 | |
| PCRX Pacira BioSciences | Maintains: Overweight | $17 → $24 | $26.73 | -10.21% | 9 | Feb 28, 2025 | |
| VTRS Viatris | Maintains: Underweight | $12 → $9 | $8.46 | +6.38% | 8 | Feb 28, 2025 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Overweight | $190 → $200 | $108.80 | +83.82% | 10 | Feb 27, 2025 | |
| ELAN Elanco Animal Health | Maintains: Overweight | $20 → $19 | $13.43 | +41.47% | 13 | Feb 26, 2025 | |
| TARS Tarsus Pharmaceuticals | Maintains: Overweight | $62 → $60 | $44.08 | +36.12% | 5 | Feb 26, 2025 | |
| ZTS Zoetis | Maintains: Overweight | $242 → $244 | $168.61 | +44.71% | 16 | Feb 14, 2025 | |
| OGN Organon & Co. | Maintains: Overweight | $26 → $24 | $9.19 | +161.15% | 2 | Feb 14, 2025 | |
| PAHC Phibro Animal Health | Maintains: Underweight | $20 → $22 | $23.93 | -8.07% | 8 | Feb 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $481 → $520 | $522.21 | -0.42% | 9 | Feb 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $28 → $26 | $17.25 | +50.72% | 12 | Jan 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $150 → $160 | $104.18 | +53.58% | 15 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $17 → $17 | $15.53 | +9.47% | 13 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $22 → $18 | $10.49 | +71.59% | 5 | Jul 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $2.5 → $10 | $3.16 | +216.46% | 2 | Oct 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $8 → $7 | $0.81 | +768.81% | 7 | Oct 23, 2023 |
Evolus
Mar 5, 2025
Maintains: Overweight
Price Target: $22 → $25
Current: $9.74
Upside: +156.67%
Amneal Pharmaceuticals
Mar 3, 2025
Maintains: Overweight
Price Target: $10 → $11
Current: $7.17
Upside: +53.42%
Pacira BioSciences
Feb 28, 2025
Maintains: Overweight
Price Target: $17 → $24
Current: $26.73
Upside: -10.21%
Viatris
Feb 28, 2025
Maintains: Underweight
Price Target: $12 → $9
Current: $8.46
Upside: +6.38%
Jazz Pharmaceuticals
Feb 27, 2025
Maintains: Overweight
Price Target: $190 → $200
Current: $108.80
Upside: +83.82%
Elanco Animal Health
Feb 26, 2025
Maintains: Overweight
Price Target: $20 → $19
Current: $13.43
Upside: +41.47%
Tarsus Pharmaceuticals
Feb 26, 2025
Maintains: Overweight
Price Target: $62 → $60
Current: $44.08
Upside: +36.12%
Zoetis
Feb 14, 2025
Maintains: Overweight
Price Target: $242 → $244
Current: $168.61
Upside: +44.71%
Organon & Co.
Feb 14, 2025
Maintains: Overweight
Price Target: $26 → $24
Current: $9.19
Upside: +161.15%
Phibro Animal Health
Feb 10, 2025
Maintains: Underweight
Price Target: $20 → $22
Current: $23.93
Upside: -8.07%
Feb 4, 2025
Maintains: Overweight
Price Target: $481 → $520
Current: $522.21
Upside: -0.42%
Jan 30, 2025
Maintains: Overweight
Price Target: $28 → $26
Current: $17.25
Upside: +50.72%
Dec 16, 2024
Maintains: Overweight
Price Target: $150 → $160
Current: $104.18
Upside: +53.58%
Nov 6, 2024
Maintains: Overweight
Price Target: $17 → $17
Current: $15.53
Upside: +9.47%
Jul 25, 2024
Maintains: Overweight
Price Target: $22 → $18
Current: $10.49
Upside: +71.59%
Oct 23, 2023
Maintains: Equal-Weight
Price Target: $2.5 → $10
Current: $3.16
Upside: +216.46%
Oct 23, 2023
Maintains: Overweight
Price Target: $8 → $7
Current: $0.81
Upside: +768.81%